Cofrogliptin
CAS No. 1844874-26-5
Cofrogliptin( —— )
Catalog No. M35685 CAS No. 1844874-26-5
Cofrogliptin (HSK7653) is an orally available dipeptidyl peptidase-4 (DPP-4) inhibitor with hypoglycemic effects, which can be used to study type 2 diabetes (T2D).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 178 | Get Quote |
|
| 5MG | 275 | Get Quote |
|
| 10MG | 440 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCofrogliptin
-
NoteResearch use only, not for human use.
-
Brief DescriptionCofrogliptin (HSK7653) is an orally available dipeptidyl peptidase-4 (DPP-4) inhibitor with hypoglycemic effects, which can be used to study type 2 diabetes (T2D).
-
DescriptionCofrogliptin (HSK7653) (compound 2), a tetrahydropyran derivative, is a potent oral dipeptidyl aminopeptidase 4 (DPP-4) inhibitor with Long-acting antidiabetic efficacy. Cofrogliptin (compound 2) has a great potential for type 2 diabetes mellitus (T2DM) .
-
In VitroCofrogliptin (HSK7653) (compound 2) has the DPP-4 inhibitory activity with an IC50 value of 4.18 nM.
-
In VivoCofrogliptin (HSK7653) (compound 2) (IV: 0.5 mg/kg; PO: 2 mg/kg) exhibits extremely long half-lives and low rate of reduction of drug concentration after orally administration.Cofrogliptin (compound 2) (Single, orally, 3 mg/kg, 10 mg/kg, 30 mg/kg) increases of half-lives, has high oral exposure, low i.v. clearance and hepatic microsomal clearance after intravenous dosing. Cofrogliptin (compound 2) (Single, orally, 10 mg/kg) exhibits longe inhibition time of DPP-4 and decreases HbA1c level at the doses of 3 and 10 mg/kg in ob/ob mice. Cofrogliptin (compound 2) (Single, orally, 10 mg/kg) also has a great potential of biweekly regimen for T2DM as indicated in rhesus monkeys.Animal Model:ob/ob mice Dosage:3 mg/kg, 10 mg/kg, 30 mg/kg Administration: Single, orally, 3 mg/kg, 10 mg/kg, 30 mg/kg Result:Exhibited strong inhibition capability of plasma DPP-4 in a dose dependent manner. Animal Model:rhesus monkeys Dosage:10 mg/kg Administration:Single, orally, 10 mg/kg Result: Possessed the capability of plasma DPP-4 inhibition over 80% for at least 12 days.Remained the plasma DPP-4 inhibition rates of 76.16% and 43.41%, respectively at the end of second week and third week after administration.
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetDPP
-
RecptorDPP-4
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1844874-26-5
-
Formula Weight466.43
-
Molecular FormulaC18H19F5N4O3S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (214.39 mM; Ultrasonic )
-
SMILESC(F)(F)(F)[C@@H]1[C@@H](C[C@H](N)[C@H](O1)C2=C(F)C=CC(F)=C2)N3CC=4C(C3)=NN(S(C)(=O)=O)C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. International NonproprietaryNames for PharmaceuticalSubstances (INN)
molnova catalog
related products
-
NU1025
NU1025 is a potent PARP inhibitor with IC50 of 400 nM.
-
Trelagliptin
Trelagliptin is a highly selective, long-acting DPP-4 inhibitor. Phase 3.
-
Imigliptin dihydroch...
A novel potent, selective, orally available DPP-4 inhibitor with IC50 of 9 nM.
Cart
sales@molnova.com